Aastrom Adds Biologic-Device Offerings Through $6.5M Buy From Sanofi
This article was originally published in The Gray Sheet
The deal will give cell-therapy firm Aastrom three products: Carticel, for treatment of articular cartilage defects; Epicel, a permanent skin replacement for full thickness burns; and MACI (matrix-induced autologous chondrocyte implant), an autologous chondrocyte implant approved in Europe.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.